Cargando…

Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown remarkable success in treating skin cutaneous melanoma (SKCM); however, the response to treatment varies greatly between patients. Considering that the efficacy of ICI treatment is influenced by many factors, we selected the Fibrosheath inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ying, Haoxuan, Lin, Anqi, Liang, Junyi, Zhang, Jian, Luo, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186463/ https://www.ncbi.nlm.nih.gov/pubmed/34113648 http://dx.doi.org/10.3389/fmolb.2021.629330

Ejemplares similares

Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma
por: Zhao, Liqin, et al.
Publicado: (2022)

FAT10 is a Prognostic Biomarker and Correlated With Immune Infiltrates in Skin Cutaneous Melanoma
por: Wang, Yu, et al.
Publicado: (2022)

m6A-Related lncRNAs Are Potential Biomarkers for the Prognosis of Metastatic Skin Cutaneous Melanoma
por: Huang, Suyang, et al.
Publicado: (2021)

Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response
por: Goode, Emily F., et al.
Publicado: (2021)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
por: Zheng, Liyun, et al.
Publicado: (2021)

Editorial: Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction
por: Pellegrini, Cristina, et al.
Publicado: (2021)

The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
por: Zhang, Zhizhu, et al.
Publicado: (2021)

The Integrative Analysis Identifies Three Cancer Subtypes and Stemness Features in Cutaneous Melanoma
por: Wang, Xiaoran, et al.
Publicado: (2021)

lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma
por: Wozniak, Michal, et al.
Publicado: (2023)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Guven, Deniz Can, et al.
Publicado: (2022)

Editorial: Molecular genetics of cutaneous melanoma: current status and future direction-volume II
por: Garcia-Casado, Zaida, et al.
Publicado: (2023)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020)

Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types
por: Wu, Yuliang, et al.
Publicado: (2022)

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
por: Vanni, Irene, et al.
Publicado: (2020)

Identification of the m(6)A RNA Methylation Regulators WTAP as a Novel Prognostic Biomarker and Genomic Alterations in Cutaneous Melanoma
por: Feng, Zi-Yi, et al.
Publicado: (2021)

Epidermal Immunity and Function: Origin in Neonatal Skin
por: Visscher, Marty O., et al.
Publicado: (2022)

Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts
por: Wang, Hufei, et al.
Publicado: (2022)

Expression and clinicopathological significance of FSIP1 in breast cancer
por: Zhang, Hao, et al.
Publicado: (2015)

Immune-modulating Activity of Hydrogel Microparticles Contributes to the Host Defense in a Murine Model of Cutaneous Anthrax
por: Teunis, Allison L., et al.
Publicado: (2017)

Development and External Validation of a Novel Immune Checkpoint–Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma
por: Zhao, Enfa, et al.
Publicado: (2021)

A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma
por: Yan, Xiuwei, et al.
Publicado: (2022)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Applying Single-Cell Technology in Uveal Melanomas: Current Trends and Perspectives for Improving Uveal Melanoma Metastasis Surveillance and Tumor Profiling
por: Wang, Mona Meng, et al.
Publicado: (2021)

Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells
por: Pires, Vanessa, et al.
Publicado: (2022)

Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer
por: Xie, Xiaodong, et al.
Publicado: (2023)

Stem–Mesenchymal Signature Cell Genes Detected in Heterogeneous Circulating Melanoma Cells Correlate With Disease Stage in Melanoma Patients
por: Rapanotti, Maria Cristina, et al.
Publicado: (2020)

Comprehensive Analysis of the Relationships Between Tumor Mutation Burden With Immune Infiltrates in Cervical Cell Carcinoma
por: Zhou, Cankun, et al.
Publicado: (2020)

Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis
por: Yin, Lu, et al.
Publicado: (2021)

Phosphatase and Tensin Homolog Mutation in Immune Cell Infiltration and Clinicopathological Features of Low-Grade Gliomas
por: Feng, Peng, et al.
Publicado: (2020)

Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma
por: Liang, Fangfang, et al.
Publicado: (2021)

ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study
por: Chen, Min, et al.
Publicado: (2021)

The Genetic Germline Background of Single and Multiple Primary Melanomas
por: De Summa, Simona, et al.
Publicado: (2021)

A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2020)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma
por: Cerqueira, Otto Luiz Dutra, et al.
Publicado: (2022)

Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments
por: Yan, Chi, et al.
Publicado: (2022)

Bi-allelic mutation in Fsip1 impairs acrosome vesicle formation and attenuates flagellogenesis in mice
por: Gamallat, Yaser, et al.
Publicado: (2021)

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9mub32vft5tae87i7q4o3ae4sc